Low-Density PRP and Platelet-Poor Plasma (PPP) Hydrodissection

Low-density platelet-rich plasma (LD-PRP) and platelet-poor plasma (PPP) are autologous biologic therapies derived from a patient’s own blood and used in selected clinical contexts to support tissue recovery and relieve pain associated with nerve entrapment, scar-related adhesions, and myofascial dysfunction.

These therapies are distinct from traditional, higher-concentration PRP used for tendon or joint pathology. In hydrodissection and nerve-focused applications, the mechanical effects of fluid delivery and the low-inflammatory biologic profile of LD-PRP or PPP are central to their clinical rationale. (1-3)

About Low-density PRP (LD-PRP)

Blood plasma contains platelets, signaling proteins, cytokines, and growth factors that participate in normal tissue repair. When plasma is processed to increase platelet concentration, the resulting preparation is called platelet-rich plasma (PRP).

Low-density PRP is intentionally prepared with a lower platelet concentration and reduced inflammatory cell content compared with traditional PRP. This formulation is selected when the clinical goal is to:

  • Avoid excessive inflammatory signaling

  • Minimize post-procedure flare

  • Support recovery in neural, muscular, and scar-dominated tissues 

Emerging evidence and consensus frameworks recognize that PRP is not a single product, and that platelet dose and leukocyte content significantly influence tissue response. (4-6) Lower-density formulations may be preferable in tissues that are sensitive to inflammation, including peripheral nerves and fibrotic scar planes.

Clinical contexts where LD-PRP may be considered include:

  • Scar-related nerve irritation

  • Perineural pain syndromes

  • Muscle injury and muscle atrophy

  • Post-surgical adhesions

  • Myofascial pain with neural involvement

LD-PRP is not intended to replace tissue or guarantee regeneration. Its role is to support biologic modulation in an environment where excessive inflammation may be counterproductive. (4,6)

About platelet-poor plasma

Platelet-poor plasma (PPP) is the plasma fraction remaining after platelets have been reduced or removed during PRP preparation. PPP contains plasma proteins and fluid volume but minimal platelet-derived growth factors.

In hydrodissection and nerve hydrolysis procedures, PPP is primarily used for its mechanical properties rather than for high biologic signaling. Its clinical role is to:

  • Hydrodissect (mechanically separate) nerves from surrounding fascia or scar tissue

  • Restore nerve mobility

  • Reduce mechanical compression and tethering

 PPP is particularly useful when the therapeutic objective is tissue-plane separation rather than biological stimulation. Systematic reviews of ultrasound-guided hydrodissection demonstrate that fluid-based injectates, including plasma-based solutions, can improve pain and function in peripheral nerve entrapment syndromes by relieving mechanical compression. (1-3)

How are Low-Density PRP and PPP Made and Applied?

Patients should expect a total clinic visit of approximately two hours, with the procedural portion typically lasting 10–30 minutes.

Step 1: Blood collection

Upon arrival, a venous blood sample is obtained using sterile technique. The volume drawn is determined by the number of treatment sites, injectate type (LD-PRP vs PPP), and patient-specific factors.

Step 2: Plasma separation

In the laboratory, whole blood is processed by centrifugation to separate plasma from red blood cells.

Step 3: Controlled concentration adjustment

Depending on the intended use:

  • Platelet concentration is reduced or adjusted to create LD-PRP

  • Platelets are largely removed to prepare PPP

This controlled adjustment allows formulation of an injectate with a lower inflammatory profile than traditional PRP. Preparation typically takes about one hour and is performed under sterile conditions.

Step 4: Image-guided administration

Once prepared, LD-PRP or PPP is administered by a physician using real-time ultrasound or fluoroscopic guidance, depending on the target tissue. In hydrodissection procedures, fluid is delivered into precise tissue planes to separate nerves from adhesions or compressive structures. Visualization ensures accurate placement and controlled tissue separation. (1-3)

Step 5: Post-procedure response

LD-PRP and PPP are not immediate analgesics. Patients may experience transient soreness or pressure, followed by gradual improvement over weeks to months, depending on the tissue treated and the severity of the pathology. (1-3)

Evidence Basis and Clinical Rationale

The use of plasma-based injectates for hydrodissection is supported by a growing body of literature demonstrating that mechanical decompression of peripheral nerves can reduce pain and improve function in conditions such as carpal tunnel syndrome and other entrapment neuropathies. (1-3)

Network meta-analyses comparing injectates (saline, dextrose, corticosteroids, PRP, plasma-based solutions) indicate that injectate choice influences both efficacy and tolerability, with lower-inflammatory solutions often associated with fewer post-procedure flares. (3)

Importantly, these therapies are adjunctive and should be integrated into a broader clinical plan that includes diagnosis confirmation, activity modification, and rehabilitation when appropriate.

Regulatory Considerations

 Low-density PRP and PPP are autologous biologic preparations derived from a patient’s own blood. These products are not approved by the U.S. Food and Drug Administration (FDA) as drugs or biologics for the treatment of specific musculoskeletal or neuropathic conditions. Their clinical use is based on physician judgment, current scientific evidence, and individualized patient evaluation. No claims are made regarding guaranteed outcomes, tissue regeneration, or disease modification.

Interested in Learning More?

If you would like to learn more about whether LD-PRP or PPP hydrodissection may be appropriate for your condition, we encourage you to contact our clinic for a consultation.

References

1.     Sveva V, Farì G, Fai A, et al. Safety and efficacy of ultrasound-guided perineural hydrodissection as a minimally invasive treatment in carpal tunnel syndrome: a systematic review. Journal of Personalized Medicine. 2024;14(2):154. doi:10.3390/jpm14020154.

2.     Wu YT, Ho TY, Chou YC, et al. Six-month efficacy of perineural dextrose injection for carpal tunnel syndrome: a prospective, randomized, double-blind, controlled trial. Mayo Clinic Proceedings. 2017;92(8):1179–1189. doi:10.1016/j.mayocp.2017.05.025.

3.     Buntragulpoontawee M, Chang KV, Vitoonpong T, et al. The effectiveness and safety of commonly used injectates for ultrasound-guided hydrodissection in peripheral nerve entrapment syndromes: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2021;11:621150. doi:10.3389/fphar.2020.621150.

4.     DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. American Journal of Sports Medicine. 2012;40(4):106–114. doi:10.1177/0363546512442374.

5.     Magalon J, Chateau AL, Bertrand B, et al. DEPA classification: a proposal for standardising PRP use. BMJ Open Sport & Exercise Medicine. 2016;2:e000060. doi:10.1136/bmjsem-2015-000060.

6.     Dohan Ehrenfest DM, Andia I, Zumstein MA, et al. Classification of platelet concentrates (PRP, PRF) and their biologic properties. Trends in Biotechnology. 2014;32(1):21–32. doi:10.1016/j.tibtech.2013.10.002.